Last reviewed · How we verify

NCT05586126

AnaConDa-therapy in COVID-19 Patients

Terminated Last updated 19 October 2022
What this trial tests

trial testing Sevoflurane in COVID-19 in 42 participants. Terminated before completion.

Timeline
1 October 2020
Primary endpoint
27 January 2021
1 July 2022

Quick facts

Lead sponsorJeroen Bosch Ziekenhuis
StatusTerminated
Study typeOBSERVATIONAL
Enrollment42
Start date1 October 2020
Primary completion27 January 2021
Estimated completion1 July 2022
Sites1 location across Netherlands

Drugs / interventions tested

Conditions studied

Sponsor

Jeroen Bosch Ziekenhuis

Who can join

18 and older, any sex, with COVID-19 or SARS CoV-2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

COVID 19-pneumonia may evolve into respiratory insufficiency for which invasive mechanical ventilation is required. Recently, inhaled anesthetics have become available for sedation of critically ill patients. Based upon recent research, these anesthetics may provide advantages in improvement of P/F ratio in ARDS patients. However, up to now, its effects on COVID-19 pneumonia patients is unknown; therefore, this study was designed as a plan to investigate whether the use of inhaled sevoflurane leads to improvement of oxygenation compared to intravenous sedatives in mechanically ventilated COVID-19 patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Sevoflurane

Trials testing the same drug.

Other recruiting trials for COVID-19

Currently open trials in the same condition.

Other Jeroen Bosch Ziekenhuis trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05586126.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing